Is uncertainty concerning the regulation of antimicrobial drug trials stifling investment in infectious disease treatments? Here, experts from a large pharma company and a biotech firm provide their perspectives.
The US Food and Drug Administration (FDA) has recently rejected new antibiotics for common infections citing the requirement that the drugs intended to treat non-serious infections prove superior to placebo rather than active controls. With the introduction of more stringent statistical criteria, inconsistencies in bacterial-susceptibility testing and renewed debate over placebo-controlled testing in antibiotic trials, how much is the regulatory regime deterring investment in the sector?
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brenner, R., Ellis-Grosse, E. & Echols, R. Moving goalposts—regulatory oversight of antibacterial drugs. Nat Biotechnol 24, 1515 (2006). https://doi.org/10.1038/nbt1206-1515
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1515
This article is cited by
-
Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections
European Journal of Clinical Microbiology & Infectious Diseases (2018)